Search

Contrast-enhancing magnetic resonance mechanism, employing either positive or negative signal changes, has contrast-specific signal characteristics. Although highly sensitive, negative contrast typically decreases the resolution and spatial specificity of MRI, whereas positive contrast lacks a high contrast-to-noise ratio but offers high spatial accuracy. To overcome these individual limitations, dual-contrast acquisitions were performed using iron oxide nanoparticles and a pair of MRI acquisitions. Specifically, vascular signals in MR angiography were positively enhanced using ultrashort echo (UTE) acquisition, which provided highly resolved vessel structures with increased vessel/tissue contrast. In addition, fast low angle shot (FLASH) acquisition yielded strong negative vessel contrast, resulting in the higher number of discernible vessel branches than those obtained from the UTE method. Taken together, the high sensitivity of the negative contrast delineated ambiguous vessel regions, whereas the positive contrast effectively eliminated the false negative contrast areas (e.g., airways and bones), demonstrating the benefits of the dual-contrast method. From the Clinical Editor In this study, the MRI properties of iron oxide nanoparticles were studied in an animal model. These contrast agents are typically considered negative contrast materials, leading to signal loss on T2* weighted images, but they also have known T1 effects as well, which is lower than that of standard positive contrast agents (like gadolinium or manganese) but is still detectable. This dual property was utilized in this study, demonstrating high sensitivity of the negative contrast in delineating ambiguous vessel regions, whereas the positive contrast eliminated false negative contrast areas (areas giving rise to susceptibility effects). [ABSTRACT FROM AUTHOR]

High sensitivity at ultra-high field (UHF) and sufficient potential to penetrate the brain are the most desirable characteristics in the development of contrast agents (CAs) for magnetic resonance imaging (MRI). However, incorporating such qualities into a single nanocarrier is challenging. Herein, we report a new strategy for a highly brain-permeable MR CA with high sensitivity at UHF by loading dysprosium chelates (DyL) in apoferritin cavities (Apo-DyL). We also design the chelate ligand structure to increase DyL loading capacity within the apoferritin cavity. Using the intracerebroventricular (ICV) injection approach as a new delivery route for Apo-DyL, we demonstrate that apoferritin loaded with DyL can penetrate the brain–ventricular barrier and diffuse into the brain. This brain-permeable capability is unique to Apo-DyL, compared with other types of nanoparticles used in MRI. Apo-DyL also shows significant increase in MR sensitivity of DyL at UHF. Furthermore, based on brain tumor imaging at UHF, Apo-DyL can significantly enhance the tumor for a lower dose of the CA than the previously reported Gd- or Mn-loaded apoferritin nanoplatform. Therefore, Apo-DyL can be a novel nanoplatform that is a highly sensitive and versatile MR CA for UHF brain imaging. [ABSTRACT FROM AUTHOR]